Detalhe da pesquisa
1.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Lung Cancer
; 102: 65-73, 2016 12.
Artigo
Inglês
| MEDLINE | ID: mdl-27987591